- Home
- CGO vs SRTS Comparison
CGO vs SRTS Comparison
Compare CGO & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | SRTS |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.3M | 52.5M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CGO | SRTS |
|---|---|---|
| Price | $14.05 | $3.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 33.2K | ★ 82.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,482,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $34.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.71 | $2.82 |
| 52 Week High | $14.02 | $5.92 |
Technical Indicators
Market Signals| Indicator | CGO | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 71.54 | 35.83 |
| Support Level | $11.38 | $3.03 |
| Resistance Level | N/A | $3.24 |
| Average True Range (ATR) | 0.23 | 0.23 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 96.77 | 24.64 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.